PDRN vs PN Injectable: Which Polynucleotide Treatment Should You Choose for Your Clinic in 2026?

Polynucleotide injectables are becoming one of the fastest-growing categories in regenerative aesthetics across Europe. The European polynucleotide injectables market generated an estimated $31.9 million in 2025 and is projected to reach $237 million by 2033, representing a forecast CAGR of 26.5% between 2026 and 2033.

Clinic adoption is growing too. In the UK, approximately 3,000 providers were offering polynucleotide treatments by March 2025, around twice as many as twelve months earlier.

As clinics expand their regenerative treatment portfolios, one question is becoming increasingly relevant: what is the difference between PN and PDRN injectables?

Although both are DNA-derived regenerative materials, they are not necessarily identical. Understanding their molecular characteristics, mechanisms and clinical positioning can help practitioners evaluate which approach best fits their treatment objectives.

What Is the Difference Between PN and PDRN?

PN (polynucleotide) and PDRN (polydeoxyribonucleotide) both consist of DNA-derived fragments, but current scientific literature distinguishes them partly according to their molecular characteristics.

PN generally refers to longer DNA fragments and has become particularly associated with regenerative aesthetic treatments focused on skin quality, elasticity and tissue remodelling.

PDRN generally consists of relatively shorter DNA fragments and has a longer research history in tissue regeneration and wound healing. Its biological activity has notably been associated with activation of the adenosine A2A receptor, a pathway involved in tissue repair and inflammatory regulation.

However, PN and PDRN terminology has not always been used consistently in scientific and commercial literature. Practitioners should therefore evaluate the composition and documentation of each individual product rather than relying on the category name alone.

Although the two categories share regenerative properties, PN injectables are generally preferred for aesthetic skin improvement, while PDRN treatments are frequently selected when tissue healing is the primary objective. 

Which Injectable Is Best for Your Clinical Indications?

Selecting a polynucleotide injectable depends on several factors, including the patient's skin condition, medical history, treatment objectives and the practitioner's clinical assessment. Both PN and PDRN injectables are used in aesthetic medicine for different regenerative purposes, and product selection should always follow the manufacturer's instructions for use and applicable clinical guidelines. 

Skin Rejuvenation

PN injectables are widely used in aesthetic medicine to improve skin quality, support collagen production and enhance skin elasticity. They are commonly incorporated into treatment protocols designed to address visible signs of skin ageing. The choice of product and treatment protocol should be determined by the treating healthcare professional based on the patient's individual needs.

Products such as Plinest and Nucleofill are among the polynucleotide injectables available for this indication in Europe. 

Under-Eye Treatments

The delicate periorbital area requires careful product selection and injection technique. Polynucleotide injectables are used by some practitioners to improve skin quality and the appearance of fine lines in this area while preserving natural facial characteristics. Suitability depends on individual patient assessment and the intended clinical outcome.

Products including Plinest Eye and Nucleofill Soft Eyes are available for treatments targeting the under-eye area. 

Acne Scars

Polynucleotide injectables may be incorporated into comprehensive treatment plans for atrophic acne scars, either as standalone procedures or alongside other aesthetic techniques such as microneedling or energy-based treatments where clinically appropriate. The treatment approach varies according to scar type, severity and patient characteristics.

Products such as Plinest and Nucleofill Medium are among the options available for practitioners.

Photoaged Skin

Photoaged skin is characterised by collagen degradation, reduced elasticity and uneven skin texture resulting from long-term UV exposure. PN injectables are used in clinical practice as part of skin rejuvenation protocols intended to improve overall skin quality over time. Product selection should be based on the practitioner's assessment and treatment objectives.

Among the products available in Europe, Ameela  and Plinest are commonly used in regenerative aesthetic procedures. 

Sensitive Skin

Patients with sensitive or compromised skin may require treatment protocols that prioritise skin regeneration and recovery. Depending on the clinical objective, both PN and PDRN injectables may be considered by healthcare professionals. The choice of product depends on the patient's condition, medical history and the intended treatment outcome.

Several CE-marked products, including Ameela and selected PDRN-based injectables, are available within this treatment category. 

After Laser or RF Procedures

Regenerative injectables may be incorporated into post-procedure protocols following treatments such as fractional laser or radiofrequency microneedling, where appropriate. The timing of treatment and product selection depend on the procedure performed, the patient's recovery and the practitioner's clinical judgement.

Various PN and PDRN injectables, including Plinest, are available for use by qualified healthcare professionals in accordance with their intended indications and the manufacturer's instructions. 

Patients should always consult a qualified healthcare professional to determine the most appropriate treatment plan.

Which Product Fits Your Practice?

The most suitable polynucleotide injectable depends on your patient profile, treatment protocols and clinical objectives. Aesthetic and anti-ageing clinics often look for versatile products that support skin quality and collagen stimulation, while dermatology practices may prioritise regenerative treatments for scars, photoaged skin and post-procedure recovery. 

What to Compare Before Buying a Polynucleotide Injectable

When selecting a polynucleotide injectable, clinics should verify that the product is CE marked for the intended European market and sourced through an authorised distributor, such as RM365 Netherlands. Clinical documentation, manufacturer reputation, regulatory compliance and batch traceability are all important considerations. Stock availability, storage requirements, delivery times and responsive customer support can also help ensure a consistent supply for everyday clinical practice.

Why Clinics Buy Their Polynucleotide Injectables from RM365 Netherlands

RM365 Netherlands supplies CE-marked polynucleotide injectables to aesthetic professionals across Europe through authorised distribution channels. Clinics choose RM365 for genuine products with documented batch traceability, fast European delivery and professional customer support. The portfolio includes several leading brands, allowing practices to source multiple regenerative injectable solutions from a single supplier with secure ordering and consistent availability.

For the latest stock availability and ordering information, healthcare professionals can visit the individual product pages or contact the RM365 team.

Frequently Asked Questions Before Ordering